|By PR Newswire||
|April 15, 2014 11:16 AM EDT||
LONDON, April 15, 2014 /PRNewswire/ --
On Monday, April 14, 2014, the NASDAQ Composite ended at 4,022.69, up 0.57%, the Dow Jones Industrial Average advanced 0.91%, to finish the day at 16,173.24, and the S&P 500 closed at 1,830.61, up 0.82%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, while the same has fallen by 1.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free technical research on ONVO, BMRN, VRTX and SPPI can be downloaded upon signing up at:
Organovo Holdings Inc.'s stock finished the Monday's session 13.91% lower at $6.25. A total of 4.42 million shares were traded, which is above its three months average volume of 2.65 million shares. The stock traded between $6.06 and $7.52 during the session. Organovo Holdings Inc.'s stocks have plummeted 25.77% in the previous three trading sessions, 28.57% in the last one month, and 43.54% on YTD basis. The company shares are trading below their 50-day and 200-day moving averages. Organovo Holdings Inc.'s 50-day moving average of $9.06 is above its 200-day moving average of $7.77. Moreover, shares of the company have a Relative Strength Index of 34.96. Sign up today to read free research on ONVO at:
On Monday, Shares in BioMarin Pharmaceutical Inc. fluctuated between $56.45 and $59.88 before ending session 0.21% higher at $57.37. BioMarin Pharmaceutical Inc.'s stock reported a trading volume of 2.11 million shares, as compared with its three months average volume of 1.56 million shares. BioMarin Pharmaceutical Inc.'s shares have declined 12.81% in the previous three trading sessions, 19.58% in the last three months and 18.45% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $73.29 and $68.87, respectively. Additionally, the stock has an RSI of 24.52. Sign up today to read free research on BMRN at:
Vertex Pharmaceuticals Inc.'s stock edged 0.98% lower, to close the day at $62.44. The stock recorded a trading volume of 1.68 million shares as compared with its three months average volume of 1.69 million shares. The stock oscillated between $61.19 and $65.14 during the trading session. Shares of the company traded at a PE ratio of 318.04. Vertex Pharmaceuticals Inc.'s shares have fallen by 10.74% in the previous three trading sessions, 20.28% in the last one month and 15.96% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Vertex Pharmaceuticals Inc.'s 50-day moving average of $77.25 is above its 200-day moving average of $75.76. Moreover, shares of the company have an RSI of 32.37. Sign up today to read free research on VRTX at:
On Monday, Shares in Spectrum Pharmaceuticals Inc. registered a trading volume of 0.67 million shares, as compared with its three months average volume of 0.92 million shares. The stock ended the day at $6.77, down 0.29% and at an intraday range of $6.53 and $6.98. Spectrum Pharmaceuticals Inc.'s shares have lost 12.19% in the previous three trading sessions, 15.27% in the last one month and 23.50% on YTD basis. The company stock is trading below its 50-day and 200-day moving averages of $8.03 and $8.44, respectively. Furthermore, the shares of the company have an RSI of 31.76. Sign up today to read free research on SPPI at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.